ArticleNature medicine2023
Neoplasia risk in patients with Lynch syndrome treated with immune checkpoint blockade.
Open access · greenAbstract read
In one paragraph
Article in Nature medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
7.9field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 31 citations in OpenAlex.
- Trial
- Colonic Polyp Regression After Nous-209 Cancer Immunotherapy: A Clinical Trial Case Report.Journal of immunotherapy and precision oncology · 2026Article
- Structured surveillance in Lynch syndrome: effectiveness, limitations, and unmet needs.ESMO gastrointestinal oncology · 2026Article
- Incidence of B-cell Malignancies in Patients with Lung Cancer Receiving PD-1 Blockade Therapy.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- Identification of the Lynch syndrome and Lynch-like syndrome specific somatic mutations in microsatellite instability-high colorectal cancer cases.Surgery today · 2026Article
- Reprogramming T cell-myeloid crosstalk overcomes immune resistance in colorectal cancer.Cell reports. Medicine · 2026Article
- Preventive vaccines for hereditary cancer syndromes.Nature medicine · 2026Article
- Lynch Syndrome as a Spectrum of Four Distinct Genetic Disorders: Toward Genotype-Guided Precision Management in the NGS Era.Cancers · 2026Review
- Whole genome sequencing-based analysis of genetic predisposition to adult glioblastoma.NPJ genomic medicine · 2025Article
- Therapeutic targeting of mismatch repair-deficient cancers.Nature reviews. Clinical oncology · 2025Review
- Article
- Bibliometric analysis of immune dysregulation and immunotherapy in mismatch repair-deficient colon cancer.Discover oncology · 2025Article
- Vanished! Auto-amputated Ileal Polyp in a Patient with Lynch Syndrome.Digestive diseases and sciences · 2025Article
- MMRNet: Ensemble deep learning models for predicting mismatch repair deficiency in endometrial cancer from histopathological images.Cell reports. Medicine · 2025Article
- Interview with the World Class Authorities Frontiers of Cancer Research: An exclusive interview with Professor Luis Diaz.Annals of gastroenterological surgery · 2025Article
- Early treatment discontinuation in patients with deficient mismatch repair or microsatellite instability high metastatic colorectal cancer receiving immune checkpoint inhibitors.Journal for immunotherapy of cancer · 2025Article
- Colorectal cancers associated with mismatch repair deficiency.Frontiers in medicine · 2025Review
- Hereditary Colorectal Cancer: Clinical Implications of Genomic Medicine and Precision Oncology.Journal of the anus, rectum and colon · 2025Review
- AI-driven transformation of precision medicine: a comprehensive narrative review of key application areas, emerging paradigms, and future directions.Frontiers in public health · 2025Review
- Gastrointestinal Cancer Precursor Conditions and Their Detection.Hematology/oncology clinics of North America · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
38 authors at 1 institution in 1 country.
Emily C HarroldDivision of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Michael B FooteDivision of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0003-3027-2405
Benoit RousseauDivision of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0002-1594-4827
Henry WalchMarie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0003-1188-350X
Yelena KemelNiehaus Center for Inherited Cancer Genomics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0002-5042-5651
Allison L RichardsMarie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Fergus KeaneDivision of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Andrea CercekDivision of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Rona YaegerDivision of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0002-7233-5454
Dana RathkopfDivision of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Neil H SegalDivision of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Zalak PatelDivision of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Anna MaioDivision of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Matilde BorioDivision of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Eileen M O'ReillyDivision of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Diane ReidyDivision of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Avni DesaiDivision of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Yelena Y JanjigianDivision of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Yonina R Murciano-GoroffDivision of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0001-9027-2891
Maria I CarloDivision of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0002-4786-7408
Alicia LathamDivision of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Ying L LiuDivision of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Michael F WalshDivision of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
David IlsonDivision of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0003-0831-2247
Jonathan E RosenbergDivision of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Arnold J MarkowitzWeill Cornell Medical College, New York, NY, USA.
Martin R WeiserWeill Cornell Medical College, New York, NY, USA.ORCID 0000-0002-9577-7984
Anthony M RossiWeill Cornell Medical College, New York, NY, USA.
Chad VanderbiltMarie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0002-8114-0237
Diana MandelkerDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Chaitanya BandlamudiMarie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0003-1108-4919
Kenneth OffitDivision of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Michael F BergerWeill Cornell Medical College, New York, NY, USA.ORCID 0000-0003-3882-5000
David B SolitDivision of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0002-6614-802X
Leonard SaltzDivision of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Jinru ShiaWeill Cornell Medical College, New York, NY, USA.ORCID 0000-0002-4351-2511
Luis A DiazDivision of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0002-7079-8914
Zsofia K StadlerDivision of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. stadlerz@mskcc.org.ORCID 0000-0002-6985-2864
Memorial Sloan Kettering Cancer Center · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4MClinical and Translational Science AwardUL1TR001873 · NCATS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI REILLY, MUREDACH P · 2016 to 2025
$99.0MDisparities in COVID Disease Severity and Outcomes in New York CityUL1TR002384 · NCATS · WEILL MEDICAL COLL OF CORNELL UNIV · PI JULIANNE L IMPERATO-MCGINLEY · 2017 to 2026
$86.2MSPORE In Prostate CancerP50CA092629 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Yu Chen, MICHAEL J MORRIS · 2001 to 2026
$63.0MClinical and Translational Science CenterUL1TR000457 · NCATS · WEILL MEDICAL COLL OF CORNELL UNIV · PI IMPERATO-MCGINLEY, JULIANNE L · 2012 to 2016
$46.0MSPORE in Bladder CancerP50CA221745 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI OSTROVNAYA, IRINA · 2018 to 2024
$11.8MMSK Paul Calabresi Career Development Award for Clinical OncologyK12CA184746 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Omar Abdel-Wahab, Simon N. Powell · 2015 to 2026
$8.3MDefining the role of GNAS in gastrointestinal metastasisK08CA279922 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Michael Foote · 2023 to 2026
$1.1MNeoadjuvant PD-1 blockade in mismatch repair deficient rectal cancerR21CA252519 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI CERCEK, ANDREA · 2021 to 2022
$451kNCATS NIH HHS UL1 TR000457NCATS NIH HHS UL1 TR001873NCATS NIH HHS UL1 TR002384NCI NIH HHS K08 CA279922NCI NIH HHS K12 CA184746NCI NIH HHS P30 CA008748NCI NIH HHS P50 CA092629NCI NIH HHS P50 CA221745NCI NIH HHS R21 CA252519
Abstract
Metastatic and localized mismatch repair-deficient (dMMR) tumors are exquisitely sensitive to immune checkpoint blockade (ICB). The ability of ICB to prevent dMMR malignant or pre-malignant neoplasia development in patients with Lynch syndrome (LS) is unknown. Of 172 cancer-affected patients with LS who had received ≥1 ICB cycles, 21 (12%) developed subsequent malignancies after ICB exposure, 91% (29/32) of which were dMMR, with median time to development of 21 months (interquartile range, 6-38). Twenty-four of 61 (39%) ICB-treated patients who subsequently underwent surveillance colonoscopy had premalignant polyps. Within matched pre-ICB and post-ICB follow-up periods, the overall rate of tumor development was unchanged; however, on subgroup analysis, a decreased incidence of post-ICB visceral tumors was observed. These data suggest that ICB treatment of LS-associated tumors does not eliminate risk of new neoplasia development, and LS-specific surveillance strategies should continue. These data have implications for immunopreventative strategies and provide insight into the immunobiology of dMMR tumors.
Indexed as
Colorectal NeoplasmsColorectal Neoplasms, Hereditary NonpolyposisBrain NeoplasmsHumansImmune Checkpoint InhibitorsNeoplastic Syndromes, HereditaryImmune Checkpoint Inhibitors
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.